PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation
Abstract
Authors
M. Bonafede S.R. Gandra K.M. Fox K. Wilson